Gufic Biosciences is currently trading at Rs. 72.30, up by 3.75 points or 5.47% from its previous closing of Rs. 68.55 on the BSE.
The scrip opened at Rs. 71.85 and has touched a high and low of Rs. 73.75 and Rs. 71.25 respectively. So far 80,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 77.40 on 18-May-2017 and a 52 week low of Rs. 33.30 on 29-Sep-2016.
Last one week high and low of the scrip stood at Rs. 73.75 and Rs. 64.00 respectively. The current market cap of the company is Rs. 558.85 crore.
The promoters holding in the company stood at 69.98%, while Institutions and Non-Institutions held 0.20% and 29.82% respectively.
Gufic Biosciences has received two Patent Certificates from the Intellectual Property India, The Patent Office. The Government of India, has granted patents to the company for the following formulations - ‘A Freeze Dried Pharmaceutical Composition and Process for Preparation Thereof i.e., Process for Preparation of Parental Formulation of Anidulafungin’ and ‘A Freeze Dried Parental Composition of Tigecycline and Process for Preparation Thereof’. The company is in the process of applying the above patents in other countries as well.
Gufic Biosciences is engaged in diversified business viz. Pharma, Healthcare, Bio- Technology, Seeds, Herbal etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: